84 FR 115 pgs. 27791-27792 - National Institute on Drug Abuse; Notice of Closed Meetings
Type: NOTICEVolume: 84Number: 115Pages: 27791 - 27792
Pages: 27791, 27792FR document: [FR Doc. 2019-12527 Filed 6-13-19; 8:45 am]
Agency: Health and Human Services Department
Sub Agency: National Institutes of Health
Official PDF Version: PDF Version
[top]
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.
[top]
Name of Committee: National Institute on Drug Abuse Special Emphasis Panel; SEP for NIDA Medications Development.
Date: June 25, 2019.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate cooperative agreement applications.
Place: National Institutes of Health, Neuroscience Center Building (NSC), 6001 Executive Boulevard, Rockville, MD 20852 (Telephone Conference Call).
Contact Person: Ivan K. Navarro, Ph.D., Scientific Review Officer, Office of Extramural Policy and Review, Division of Extramural Research, National Institute on Drug Abuse, NIH, DHHS, 6001 Executive Boulevard, Room 4242, MSC 9550, Bethesda, MD 20892, 301-827-5833, ivan.navarro@nih.gov .
Name of Committee: National Institute on Drug Abuse Special Emphasis Panel; Laboratories for Early Clinical Evaluation of Pharmacotherapies for Substance Use Disorders (UG1) Clinical Trials Required.
Date: June 25, 2019.
Time: 11:30 a.m. to 4:00 p.m.
Agenda: To review and evaluate cooperative agreement applications.
Place: National Institutes of Health, Neuroscience Center Building (NSC), 6001 Executive Boulevard, Rockville, MD 20852 (Telephone Conference Call).
Contact Person: Ivan K. Navarro, Ph.D., Scientific Review Officer, Office of Extramural Policy and Review, Division of Extramural Research, National Institute on Drug Abuse, NIH, DHHS, 6001 Executive Boulevard, Room 4242, MSC 9550, Bethesda, MD 20892, 301-827-5833, ivan.navarro@nih.gov .
(Catalogue of Federal Domestic Assistance Program Nos.: 93.279, Drug Abuse and Addiction Research Programs, National Institutes of Health, HHS)
Dated: June 10, 2019.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2019-12527 Filed 6-13-19; 8:45 am]
BILLING CODE 4140-01-P